Having worked at the largest synthetic DNA manufacturer (at least they were, I think they still are)... a lot of his information is just wrong. There is a huge incentive to lowering the cost of producing oligos and synthetic genes. This is actually a very interesting time in the space (shoutout AnsaBio).

I encourage him to continue explore new ways of making DNA, but understanding the market is very different from building off an expired patent.

I’ve spoken to the CEO of Ansa bio about this topic and they aren’t focused on lowering prices, but increasing what can be built.

I would like to know what specifically you think I am wrong about, though. Always happy to improve my thinking.